Clinical trials
Myelodysplastic Syndromes trials in Sweden
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 5 |
| Terminated | 5 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 7 |
| Nordic MDS Group | 3 |
| Novartis Pharmaceuticals | 3 |
| Bristol-Myers Squibb | 2 |
| Celgene Corporation | 2 |
| Traws Pharma, Inc. | 2 |
| Astex Pharmaceuticals, Inc. | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Janssen Research & Development, LLC | 1 |
| Karolinska University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 29 |
| Leukemia, Myeloid, Acute | 7 |
| Leukemia, Myelomonocytic, Chronic | 7 |
| Anemia | 5 |
| Anemia, Refractory, with Excess of Blasts | 5 |
| Leukemia | 3 |
| Thrombocytopenia | 3 |
| Cytopenia | 2 |
| Myeloproliferative Disorders | 2 |
| Anemia, Refractory | 1 |
Trials
Showing 26 to 29 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.